Skip to main content
Top
Published in: Calcified Tissue International 3/2009

01-03-2009

Kinetics of Calcium Oxalate Crystal Growth in the Presence of Osteopontin Isoforms: An Analysis by Scanning Confocal Interference Microcopy

Published in: Calcified Tissue International | Issue 3/2009

Login to get access

Abstract

Proteins that inhibit the growth and aggregation of calcium oxalate crystals play important roles in the prevention of kidney stone disease. One such protein is osteopontin (OPN), which inhibits the formation of calcium oxalate monohydrate (COM) in a phosphorylation-dependent manner. To determine the role of phosphate groups in the inhibition of COM growth by OPN, we used scanning confocal interference microscopy to compare the effects of highly phosphorylated OPN from cow milk, less phosphorylated OPN from rat bone, and nonphosphorylated recombinant OPN. COM growth was measured in the principal crystallographic directions <001>, <010>, and <100>, representing lattice-ion addition to {121}, {010}, and {100} faces, respectively. While the shapes of growth curves were very consistent from crystal to crystal, absolute growth rates varied widely. To control for this, results were expressed as changes in the aspect ratios <010>/<001> and <100>/<001>. Compared to control, bone OPN increased <010>/<001> and had no effect on <100>/<001>; milk OPN had no effect on <010>/<001>and decreased <100>/<001>; recombinant OPN had no significant effect on either aspect ratio. These findings indicate that milk OPN interacts with COM crystal faces in order of preference {100} > {121} ≈ {010}, whereas bone OPN interacts in order of preference {100}≈{121} > {010}. As {100} is the most Ca2+-rich face of COM, while {010} is the least Ca2+-rich, it appears that the OPN-mediated inhibition of COM growth occurs through a nonspecific electrostatic interaction between Ca2+ ions of the crystal and phosphate groups of the protein.
Footnotes
1
The convention used for indexing the faces of COM is that of Tazzoli and Domenghetti [26].
 
2
The Miller indices used by these authors have been converted to those used in the present study.
 
Literature
1.
go back to reference Herring LC (1962) Observations on the analysis of ten thousand urinary calculi. J Urol 88:545–562PubMed Herring LC (1962) Observations on the analysis of ten thousand urinary calculi. J Urol 88:545–562PubMed
2.
4.
go back to reference Marangella M, Bagnis C, Bruno M, Vitale C, Petrarulo M, Ramello A (2004) Crystallization inhibitors in the pathophysiology and treatment of nephrolithiasis. Urol Int 72(Suppl 1):6–10PubMedCrossRef Marangella M, Bagnis C, Bruno M, Vitale C, Petrarulo M, Ramello A (2004) Crystallization inhibitors in the pathophysiology and treatment of nephrolithiasis. Urol Int 72(Suppl 1):6–10PubMedCrossRef
5.
go back to reference Kumar V, Lieske JC (2006) Protein regulation of intrarenal crystallization. Curr Opin Nephrol Hypertens 15:374–380PubMed Kumar V, Lieske JC (2006) Protein regulation of intrarenal crystallization. Curr Opin Nephrol Hypertens 15:374–380PubMed
6.
go back to reference Hunter GK, Kyle CL, Goldberg HA (1994) Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J 300:723–728PubMed Hunter GK, Kyle CL, Goldberg HA (1994) Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J 300:723–728PubMed
7.
go back to reference Shiraga H, Min W, VanDusen WJ, Clayman MD, Miner D, Terrell CH, Sherbotie JR, Foreman JW, Przysiecki C, Nielson EG, Hoyer JR (1992) Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 89:426–430PubMedCrossRef Shiraga H, Min W, VanDusen WJ, Clayman MD, Miner D, Terrell CH, Sherbotie JR, Foreman JW, Przysiecki C, Nielson EG, Hoyer JR (1992) Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 89:426–430PubMedCrossRef
8.
go back to reference Worcester EM, Blumenthal SS, Beshensky AM, Lewand DL (1992) The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J Bone Miner Res 7:1029–1036PubMedCrossRef Worcester EM, Blumenthal SS, Beshensky AM, Lewand DL (1992) The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J Bone Miner Res 7:1029–1036PubMedCrossRef
9.
go back to reference Wesson JA, Ganne V, Beshensky AM, Kleinman JG (2005) Regulation by macromolecules of calcium oxalate crystal aggregation in stone formers. Urol Res 33:206–212PubMedCrossRef Wesson JA, Ganne V, Beshensky AM, Kleinman JG (2005) Regulation by macromolecules of calcium oxalate crystal aggregation in stone formers. Urol Res 33:206–212PubMedCrossRef
10.
go back to reference Qiu SR, Wierzbicki A, Orme CA, Cody AM, Hoyer JR, Nancollas GH, Zepeda S, De Yoreo JJ (2004) Molecular modulation of calcium oxalate crystallization by osteopontin and citrate. Proc Natl Acad Sci USA 101:1811–1815PubMedCrossRef Qiu SR, Wierzbicki A, Orme CA, Cody AM, Hoyer JR, Nancollas GH, Zepeda S, De Yoreo JJ (2004) Molecular modulation of calcium oxalate crystallization by osteopontin and citrate. Proc Natl Acad Sci USA 101:1811–1815PubMedCrossRef
11.
go back to reference Wesson JA, Worcester EM, Wiessner JH, Mandel NS, Kleinman JG (1998) Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney Int 53:952–957PubMedCrossRef Wesson JA, Worcester EM, Wiessner JH, Mandel NS, Kleinman JG (1998) Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney Int 53:952–957PubMedCrossRef
12.
go back to reference Taller A, Grohe B, Rogers K, Goldberg HA, Hunter GK (2007) Specific adsorption of osteopontin and synthetic polypeptides to calcium oxalate monohydrate crystals. Biophys J 93:1768–1777PubMedCrossRef Taller A, Grohe B, Rogers K, Goldberg HA, Hunter GK (2007) Specific adsorption of osteopontin and synthetic polypeptides to calcium oxalate monohydrate crystals. Biophys J 93:1768–1777PubMedCrossRef
13.
go back to reference Jiang XJ, Feng T, Chang LS, Kong XT, Wang G, Zhang ZW, Guo YL (1998) Expression of osteopontin mRNA in normal and stone-forming rat kidney. Urol Res 26:389–394PubMedCrossRef Jiang XJ, Feng T, Chang LS, Kong XT, Wang G, Zhang ZW, Guo YL (1998) Expression of osteopontin mRNA in normal and stone-forming rat kidney. Urol Res 26:389–394PubMedCrossRef
14.
go back to reference Kohri K, Nomura S, Kitamura Y, Nagata T, Yoshioka K, Iguchi M, Yamate T, Umekawa T, Suzuki Y, Sinohara H, Kurita T (1993) Structure and expression of the mRNA encoding urinary stone protein (osteopontin). J Biol Chem 268:15180–15184PubMed Kohri K, Nomura S, Kitamura Y, Nagata T, Yoshioka K, Iguchi M, Yamate T, Umekawa T, Suzuki Y, Sinohara H, Kurita T (1993) Structure and expression of the mRNA encoding urinary stone protein (osteopontin). J Biol Chem 268:15180–15184PubMed
15.
go back to reference Yasui T, Fujita K, Sasaki S, Sato M, Sugimoto M, Hirota S, Kitamura Y, Nomura S, Kohri K (1999) Expression of bone matrix proteins in urolithiasis model rats. Urol Res 27:255–261PubMedCrossRef Yasui T, Fujita K, Sasaki S, Sato M, Sugimoto M, Hirota S, Kitamura Y, Nomura S, Kohri K (1999) Expression of bone matrix proteins in urolithiasis model rats. Urol Res 27:255–261PubMedCrossRef
16.
go back to reference Wesson JA, Johnson RJ, Mazzali M, Beshensky AM, Stietz S, Giachelli C, Liaw L, Alpers CE, Couser WG, Kleinman JG, Hughes J (2003) Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 14:139–147PubMedCrossRef Wesson JA, Johnson RJ, Mazzali M, Beshensky AM, Stietz S, Giachelli C, Liaw L, Alpers CE, Couser WG, Kleinman JG, Hughes J (2003) Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 14:139–147PubMedCrossRef
17.
go back to reference Mo L, Huang HY, Zhu XH, Shapiro E, Hasty DL, Wu XR (2004) Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int 66:1159–1166PubMedCrossRef Mo L, Huang HY, Zhu XH, Shapiro E, Hasty DL, Wu XR (2004) Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int 66:1159–1166PubMedCrossRef
18.
go back to reference Sørensen ES, Højrup P, Petersen TE (1995) Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites. Protein Sci 4:2040–2049PubMedCrossRef Sørensen ES, Højrup P, Petersen TE (1995) Posttranslational modifications of bovine osteopontin: identification of twenty-eight phosphorylation and three O-glycosylation sites. Protein Sci 4:2040–2049PubMedCrossRef
19.
go back to reference Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sorensen ES (2005) Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 390:285–292PubMedCrossRef Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sorensen ES (2005) Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 390:285–292PubMedCrossRef
20.
go back to reference Hunter GK, Grohe B, Jeffrey S, O’Young J, Sørensen ES, Goldberg HA (2009) Role of phosphate groups in inhibition of calcium oxalate crystal growth by osteopontin. Cells Tissues Organs. 189(1–4):44–50 Hunter GK, Grohe B, Jeffrey S, O’Young J, Sørensen ES, Goldberg HA (2009) Role of phosphate groups in inhibition of calcium oxalate crystal growth by osteopontin. Cells Tissues Organs. 189(1–4):44–50
21.
go back to reference Keykhosravani M, Doherty-Kirby A, Zhang C, Brewer D, Goldberg HA, Hunter GK, Lajoie G (2005) Comprehensive identification of post-translational modifications of rat bone osteopontin by mass spectrometry. Biochemistry 44:6990–7003PubMedCrossRef Keykhosravani M, Doherty-Kirby A, Zhang C, Brewer D, Goldberg HA, Hunter GK, Lajoie G (2005) Comprehensive identification of post-translational modifications of rat bone osteopontin by mass spectrometry. Biochemistry 44:6990–7003PubMedCrossRef
22.
go back to reference Christensen B, Petersen TE, Sorensen ES (2008) Post-translational modification and proteolytic processing of urinary osteopontin. Biochem J 411:53–61PubMedCrossRef Christensen B, Petersen TE, Sorensen ES (2008) Post-translational modification and proteolytic processing of urinary osteopontin. Biochem J 411:53–61PubMedCrossRef
23.
go back to reference Hoyer JR, Asplin JR, Otvos L (2001) Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int 60:77–82PubMedCrossRef Hoyer JR, Asplin JR, Otvos L (2001) Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals. Kidney Int 60:77–82PubMedCrossRef
24.
go back to reference Wang LJ, Guan XY, Tang RK, Hoyer JR, Wierzbicki A, De Yoreo JJ, Nancollas GH (2008) Phosphorylation of osteopontin is required for inhibition of calcium oxalate crystallization. J Phys Chem B 112:9151–9157PubMedCrossRef Wang LJ, Guan XY, Tang RK, Hoyer JR, Wierzbicki A, De Yoreo JJ, Nancollas GH (2008) Phosphorylation of osteopontin is required for inhibition of calcium oxalate crystallization. J Phys Chem B 112:9151–9157PubMedCrossRef
25.
go back to reference Hincke MT, St Maurice M (2000) Phosphorylation-dependent modulation of calcium carbonate precipitation by chicken eggshell matrix proteins. In: Goldberg M, Boskey A, Robinson C (eds) Chemistry and biology of mineralized tissues. American Academy of Orthopaedic Surgeons, Rosemont, IL, pp 13–17 Hincke MT, St Maurice M (2000) Phosphorylation-dependent modulation of calcium carbonate precipitation by chicken eggshell matrix proteins. In: Goldberg M, Boskey A, Robinson C (eds) Chemistry and biology of mineralized tissues. American Academy of Orthopaedic Surgeons, Rosemont, IL, pp 13–17
26.
go back to reference Tazzoli V, Domenghetti C (1980) The crystal structures of whewellite and weddellite: re-examination and comparison. Am Mineralog 65:327–334 Tazzoli V, Domenghetti C (1980) The crystal structures of whewellite and weddellite: re-examination and comparison. Am Mineralog 65:327–334
27.
go back to reference Grohe W, Rogers K, Goldberg HA, Hunter GK (2006) Crystallization kinetics of calcium oxalate hydrates studied by scanning confocal interference microscopy. J Crystal Growth 295:148–157CrossRef Grohe W, Rogers K, Goldberg HA, Hunter GK (2006) Crystallization kinetics of calcium oxalate hydrates studied by scanning confocal interference microscopy. J Crystal Growth 295:148–157CrossRef
28.
go back to reference Goldberg HA, Sodek J (1994) Purification of mineralized tissue-associated osteopontin. J Tissue Culture Methods 16:211–215CrossRef Goldberg HA, Sodek J (1994) Purification of mineralized tissue-associated osteopontin. J Tissue Culture Methods 16:211–215CrossRef
29.
go back to reference Sorensen ES, Petersen TE (1993) Purification and characterization of three proteins isolated from the proteose peptone fraction of bovine milk. J Dairy Res 60:189–197PubMedCrossRef Sorensen ES, Petersen TE (1993) Purification and characterization of three proteins isolated from the proteose peptone fraction of bovine milk. J Dairy Res 60:189–197PubMedCrossRef
30.
go back to reference Millan A (2001) Crystal growth shape of whewellite polymorphs: influence of structure distortions on crystal shape. Crystal Growth Des 1:245–254CrossRef Millan A (2001) Crystal growth shape of whewellite polymorphs: influence of structure distortions on crystal shape. Crystal Growth Des 1:245–254CrossRef
31.
go back to reference Guo SW, Ward MD, Wesson JA (2002) Direct visualization of calcium oxalate monohydrate crystallization and dissolution with atomic force microscopy and the role of polymeric additives. Langmuir 18:4284–4291CrossRef Guo SW, Ward MD, Wesson JA (2002) Direct visualization of calcium oxalate monohydrate crystallization and dissolution with atomic force microscopy and the role of polymeric additives. Langmuir 18:4284–4291CrossRef
32.
go back to reference Jung T, Sheng X, Choi CK, Kim WS, Wesson JA, Ward MD (2004) Probing crystallization of calcium oxalate monohydrate and the role of macromolecule additives with in situ atomic force microscopy. Langmuir 20:8587–8596PubMedCrossRef Jung T, Sheng X, Choi CK, Kim WS, Wesson JA, Ward MD (2004) Probing crystallization of calcium oxalate monohydrate and the role of macromolecule additives with in situ atomic force microscopy. Langmuir 20:8587–8596PubMedCrossRef
33.
go back to reference Addadi L, Weiner S (1985) Interactions between acidic proteins and crystals: stereochemical requirements in biomineralization. Proc Natl Acad Sci USA 82:4110–4114PubMedCrossRef Addadi L, Weiner S (1985) Interactions between acidic proteins and crystals: stereochemical requirements in biomineralization. Proc Natl Acad Sci USA 82:4110–4114PubMedCrossRef
34.
go back to reference Kile DE, Eberl DD, Hoch AR, Reddy MM (2000) An assessment of calcite crystal growth mechanisms based on crystal size distributions. Geochim Cosmochim Acta 64:2937–2950CrossRef Kile DE, Eberl DD, Hoch AR, Reddy MM (2000) An assessment of calcite crystal growth mechanisms based on crystal size distributions. Geochim Cosmochim Acta 64:2937–2950CrossRef
35.
go back to reference Kile DE, Eberl DD (2003) On the origin of size-dependent and size-independent crystal growth: influence of advection and diffusion. Am Mineralog 88:1514–1521 Kile DE, Eberl DD (2003) On the origin of size-dependent and size-independent crystal growth: influence of advection and diffusion. Am Mineralog 88:1514–1521
36.
go back to reference McCabe WL (1929) Crystal growth in aqueous solutions. Ind Eng Chem 21:30–33CrossRef McCabe WL (1929) Crystal growth in aqueous solutions. Ind Eng Chem 21:30–33CrossRef
37.
go back to reference Tomazic B, Nancollas GH (1979) Kinetics of dissolution of calcium-oxalate hydrates. J Crystal Growth 46:355–361CrossRef Tomazic B, Nancollas GH (1979) Kinetics of dissolution of calcium-oxalate hydrates. J Crystal Growth 46:355–361CrossRef
38.
go back to reference Zauner R, Jones AG (2000) Determination of nucleation, growth, agglomeration and disruption kinetics from experimental precipitation data: the calcium oxalate system. Chem Eng Sci 55:4219–4232CrossRef Zauner R, Jones AG (2000) Determination of nucleation, growth, agglomeration and disruption kinetics from experimental precipitation data: the calcium oxalate system. Chem Eng Sci 55:4219–4232CrossRef
39.
go back to reference Sheng X, Jung T, Wesson JA, Ward MD (2005) Adhesion at calcium oxalate crystal surfaces and the effect of urinary constituents. Proc Natl Acad Sci USA 102:267–272PubMedCrossRef Sheng X, Jung T, Wesson JA, Ward MD (2005) Adhesion at calcium oxalate crystal surfaces and the effect of urinary constituents. Proc Natl Acad Sci USA 102:267–272PubMedCrossRef
40.
go back to reference Qiu SR, Wierzbicki A, Salter EA, Zepeda S, Orme CA, Hoyer JR, Nancollas GH, Cody AM, De Yoreo JJ (2005) Modulation of calcium oxalate monohydrate crystallization by citrate through selective binding to atomic steps. J Am Chem Soc 127:9036–9044PubMedCrossRef Qiu SR, Wierzbicki A, Salter EA, Zepeda S, Orme CA, Hoyer JR, Nancollas GH, Cody AM, De Yoreo JJ (2005) Modulation of calcium oxalate monohydrate crystallization by citrate through selective binding to atomic steps. J Am Chem Soc 127:9036–9044PubMedCrossRef
41.
go back to reference Boskey AL, Maresca M, Ullrich W, Doty SB, Butler WT, Prince CW (1993) Osteopontin–hydroxyapatite interactions in vitro. Inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner 22:147–159PubMedCrossRef Boskey AL, Maresca M, Ullrich W, Doty SB, Butler WT, Prince CW (1993) Osteopontin–hydroxyapatite interactions in vitro. Inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner 22:147–159PubMedCrossRef
42.
go back to reference Jono S, Peinado C, Giachelli CM (2000) Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 275:20197–20203PubMedCrossRef Jono S, Peinado C, Giachelli CM (2000) Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 275:20197–20203PubMedCrossRef
43.
go back to reference Pampena DA, Robertson KA, Litvinova O, Lajoie G, Goldberg HA, Hunter GK (2004) Inhibition of hydroxyapatite formation by osteopontin phosphopeptides. Biochem J 378:1083–1087PubMedCrossRef Pampena DA, Robertson KA, Litvinova O, Lajoie G, Goldberg HA, Hunter GK (2004) Inhibition of hydroxyapatite formation by osteopontin phosphopeptides. Biochem J 378:1083–1087PubMedCrossRef
44.
go back to reference Grohe B, O’Young J, Ionescu DA, Lajoie G, Rogers KA, Karttunen M, Goldberg HA, Hunter GK (2007) Control of calcium oxalate crystal growth by face-specific adsorption of an osteopontin phosphopeptide. J Am Chem Soc 129(48):14946–14951PubMedCrossRef Grohe B, O’Young J, Ionescu DA, Lajoie G, Rogers KA, Karttunen M, Goldberg HA, Hunter GK (2007) Control of calcium oxalate crystal growth by face-specific adsorption of an osteopontin phosphopeptide. J Am Chem Soc 129(48):14946–14951PubMedCrossRef
45.
go back to reference Hauschka PV, Wians FH Jr (1989) Osteocalcin–hydroxyapatite interaction in the extracellular organic matrix of bone. Anat Rec 224:180–188PubMedCrossRef Hauschka PV, Wians FH Jr (1989) Osteocalcin–hydroxyapatite interaction in the extracellular organic matrix of bone. Anat Rec 224:180–188PubMedCrossRef
46.
go back to reference Huq NL, Cross KJ, Reynolds EC (2000) Molecular modelling of a multiphosphorylated sequence motif bound to hydroxyapatite surfaces. J Mol Model 6:35–47CrossRef Huq NL, Cross KJ, Reynolds EC (2000) Molecular modelling of a multiphosphorylated sequence motif bound to hydroxyapatite surfaces. J Mol Model 6:35–47CrossRef
47.
go back to reference Wen D, Laursen RA (1992) A model for binding of an antifreeze polypeptide to ice. Biophys J 63:1659–1662PubMedCrossRef Wen D, Laursen RA (1992) A model for binding of an antifreeze polypeptide to ice. Biophys J 63:1659–1662PubMedCrossRef
48.
go back to reference Furedi-Milhofer H, Moradian-Oldak J, Weiner S, Veis A, Mintz KP, Addadi L (1994) Interactions of matrix proteins from mineralized tissues with octacalcium phosphate. Connect Tissue Res 30:251–264PubMedCrossRef Furedi-Milhofer H, Moradian-Oldak J, Weiner S, Veis A, Mintz KP, Addadi L (1994) Interactions of matrix proteins from mineralized tissues with octacalcium phosphate. Connect Tissue Res 30:251–264PubMedCrossRef
49.
go back to reference Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS (2001) Flexible structures of SIBLING proteins, bone sialoprotein and osteopontin. Biochem Biophys Res Commun 280:460–465PubMedCrossRef Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS (2001) Flexible structures of SIBLING proteins, bone sialoprotein and osteopontin. Biochem Biophys Res Commun 280:460–465PubMedCrossRef
50.
go back to reference Gericke A, Qin C, Spevak L, Fujimoto Y, Butler WT, Sorensen ES, Boskey AL (2005) Importance of phosphorylation for osteopontin regulation of biomineralization. Calcif Tissue Int 77:45–54PubMedCrossRef Gericke A, Qin C, Spevak L, Fujimoto Y, Butler WT, Sorensen ES, Boskey AL (2005) Importance of phosphorylation for osteopontin regulation of biomineralization. Calcif Tissue Int 77:45–54PubMedCrossRef
Metadata
Title
Kinetics of Calcium Oxalate Crystal Growth in the Presence of Osteopontin Isoforms: An Analysis by Scanning Confocal Interference Microcopy
Publication date
01-03-2009
Published in
Calcified Tissue International / Issue 3/2009
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-008-9215-5

Other articles of this Issue 3/2009

Calcified Tissue International 3/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine